Q-Suite™ Enabling dosimetry after SIRT with QuiremSpheres®

QUIREM Q-Suite™ is a CE-marked proprietary software tool, that can be used to verify therapy with QuiremSpheres®. By calculating the 3D dose distribution based on SPECT or MR images, verification of dose-totumour and dose-to-tissue after the QuiremSpheres® therapy can be performed. The healthcare unit of ICT Group was involved in developing the 2nd generation of Q-Suite™. ICT Healthcare supported the customer from the creation of a user testable proof of concept to the conversion into a product.

QuiremSpheres®
QuiremSpheres® are bèta radiation emitting microspheres, containing the isotope Holmium-166, that can be used for Selective Internal Radiation Therapy (SIRT). This is a minimal invasive therapy for treatment of primary and metastatic liver tumours in which high doses to the tumours can be delivered while limiting the dose to the healthy tissue. QuiremSpheres® can be visualized with both SPECT and MR imaging, even in low concentrations, enabling quantitative dose evaluation which is critical to predict clinical effect of the treatment.

Q-Suite™
The first generation of Q-Suite™ that has been developed by Quirem was primarily a dose engine to convert MRI and/or SPECTCT images of QuiremSpheres® into 3D dose distributions. The generated 3D dose images could be imported into radiation oncology/radiotherapy software for further evaluation.

Download the full-featured Q-Suite™ Enabling dosimetry after SIRT with QuiremSpheres®, to read it by clicking the button below.